Kidney Cancer Drugs Market
Global Kidney Cancer Drugs Market Size, Share and Trend Analysis Report, By Cancer Type (Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma/Transitional Cell Carcinoma and Others), By End-User (Hospitals, Clinics, and Others), Forecast (2022-2028) Update Available - Forecast 2024-2030
The global kidney cancer drugs market is anticipated to grow at a considerable 7.1% CAGR during the forecast year. The major factor that drives the global kidney cancer drug market during the forecast period is the increasing number of people suffering from kidney cancer. As per the American Cancer Society's recent estimates, in 2019, there were about 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women). Kidney and renal pelvis cancer represent 4.2% of all new cancer cases in the United States. It was estimated that there were around 14,770 deaths in 2019, owing to Kidney and renal pelvis cancer. Furthermore, the increasing utilization of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market. When kidney cancer is spread to other organs, targeted therapies are used to control kidney cancer where chemical drugs are ineffective.
Impact of COVID-19 on Global Kidney Cancer Drugs Market
The global kidney cancer drug market has been adversely impacted by the sudden emergence of the COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, kidney cancer patients were more susceptible to COVID-19 infections than compared to an individual without cancer, as they were in an immunosuppressive state caused by the malignancy and anticancer treatment. There was a significant decrease in kidney cancer drugs and diagnosis rates globally. That had shown the negative impact for that short period.
Segmental Outlook
The global kidney cancer drugs market is segmented based on the cancer type and end-users. Based on type, the market is sub-segmented into Clear cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma/Transitional Cell Carcinoma, and Others. Based on end-users, the market is sub-segmented into hospitals, clinics, and others. Others include medical centers and pharmacies. Among these, the papillary RCC type of kidney cancer drugs segment is expected to grow during the forecast period due to increasing number of patients suffering from papillary RCC type of kidney cancer.
Global Kidney Cancer Drugs Market by Clear Cell RCC, 2021(%)
The Clear Cell RCC Segment is anticipated to hold a Major Share in the Global Kidney Cancer Drugs Market.
The clear cell RCC segment is expected to hold a prominent share in the global kidney cancer drug market due to the high prevalence of the disease and the presence of diagnostic procedures and treatment therapies. As per the National Cancer Institute of the United States, in adults, clear cell RCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma cases. Clear cell RCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases.
Regional Outlooks
The global kidney cancer drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Asia Pacific region is the considered to be the fastest-growing market due to the growing improvement in healthcare infrastructure, and development of hospitals equipped with advanced medical facilities across the region.
Global Kidney Cancer Drugs Market Growth by Region, 2022-2028
The North America Region is Expected to hold the Prominent Share in the Global Kidney Cancer Drugs Market
North America has been among the frontrunners in developing kidney cancer drugs in the healthcare industry. The market growth in North America can be mainly attributed to the growing target population, the high incidence of kidney cancer, and the strong presence of medical device manufacturers. Furthermore, the global kidney cancer drugs market is due to the increasing number of kidney cancer cases. As per the GLOBOCAN 2020 statistics, the estimated numbers of kidney cancer were 431,288.
Market Players Outlook
The major companies serving the global kidney cancer drugs market include AstraZeneca group Co., Bristol-Myers Squibb Co., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Novartis International AG, Pfizer Inc., and Others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, fundings, and new product launches. For instance, in February, Glenmark Pharmaceuticals has launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at an MRP that is approximately 96% lower than the MRP compared to the innovator brand. Furthermore, in December 2021, BDR Pharma launched a standard type of Pazopanib to the Indian market and the drug is used to treat advanced renal cell carcinoma and soft tissue sarcoma.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global kidney cancer drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Kidney Cancer DrugsMarket
- Recovery Scenario of Global Kidney Cancer DrugsMarket
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. AstraZeneca group Co.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Bristol-Myers Squibb Co.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. F. Hoffmann-La Roche Ltd.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Novartis International AG
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Pfizer Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Kidney Cancer Drugs Market by Cancer Type
4.1.1. Clear Cell RCC
4.1.2. Papillary RCC
4.1.3. Chromophobe RCC
4.1.4. Urothelial Carcinoma/Transitional Cell Carcinoma
4.1.5. Others
4.2. Global Kidney Cancer Drugs Market by End-users
4.2.1. Hospitals
4.2.2. Clinics
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. The US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott
6.2. Amgen Inc.
6.3. Bayer AG
6.4. Bristol Myers Squibb (BMS)
6.5. Corbus Pharmaceuticals, Inc.
6.6. GlaxoSmithKline plc
6.7. Genentech, Inc.
6.8. Idera Pharmaceuticals, Inc.
6.9. Lupin Ltd.
6.10. Merck & Co. Inc.
6.11. Octapharma AG
6.12. SANOFI
6.13. Takeda Pharmaceuticals Co. Ltd.
6.14. Teva Pharmaceutical Industries
6.15. Viatris Inc.
LIST OF TABLES
1. GLOBAL KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)
2. GLOBAL CLEAR CELL RCC KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL PAPILLARY RCC KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL CHROMOPHOBE RCC KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA GLOBULININ KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL OTHERS KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS,2021-2028 ($ MILLION)
8. GLOBAL KIDNEY CANCER DRUGS FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBALKIDNEY CANCER DRUGS FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL KIDNEY CANCER DRUGS FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)
15. EUROPEAN KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE,2021-2028 ($ MILLION)
20. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS,2021-2028 ($ MILLION)
21. REST OF THE WORLD KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD KIDNEY CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL KIDNEY CANCER DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL KIDNEY CANCER DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL KIDNEY CANCER DRUGS MARKET, 2021-2028 (%)
4. GLOBAL KIDNEY CANCER DRUGS MARKET SHARE BY CANCER TYPE, 2021 VS 2028 (%)
5. GLOBAL CLEAR CELL RCC KIDNEY CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL PAPILLARY RCC KIDNEY CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL CHROMOPHOBE RCC KIDNEY CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA GLOBULINKIDNEY CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBALOTHERS KIDNEY CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL KIDNEY CANCER DRUGS MARKET SHARE BY END-USERS, 2021 VS 2028 (%)
11. GLOBAL KIDNEY CANCER DRUGS FOR HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBALKIDNEY CANCER DRUGS FOR CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBALKIDNEY CANCER DRUGS FOR OTHER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL KIDNEY CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. UK KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD KIDNEY CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
